Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age
Clinical trial NCT04144179 · COMPLETED
Trial details
- NCT number
- NCT04144179
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-11-06
- Primary completion
- 2020-02-24
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.